Sorafenib Shows Promise in Treating Cholangiocarcinoma

Strategic Insights -

Researchers at the Mayo Clinic's College of Medicine have made significant discoveries regarding the treatment of cholangiocarcinoma, a type of liver cancer. According to a study published in Hepatology, sorafenib, a multikinase inhibitor, has been found to inhibit the JAK/STAT signaling pathway in cholangiocarcinoma cells, leading to the dephosphorylation of Tyr(705) phospho-STAT3. This, in turn, sensitizes cancer cells to apoptosis, or programmed cell death. The researchers also found that sorafenib treatment decreased the expression of Mcl-1 messenger RNA and protein, a STAT3 transcriptional target, and enhanced the activating phosphorylation of the phosphatase SHP2.

Key Takeaways:

  • Sorafenib inhibits the JAK/STAT signaling pathway in cholangiocarcinoma cells, leading to the dephosphorylation of Tyr(705) phospho-STAT3.
  • Sorafenib treatment sensitizes cholangiocarcinoma cells to apoptosis by reducing the expression of Mcl-1 messenger RNA and protein.
  • The researchers found that sorafenib treatment enhanced the activating phosphorylation of the phosphatase SHP2, which is involved in STAT3 dephosphorylation.
  • Sorafenib treatment also decreased tumor Tyr(705) STAT3 phosphorylation and increased tumor cell apoptosis in an orthotopic, syngeneic CCA model in rats.
  • The study found that sorafenib displayed significant tumor suppression, resulting in a survival benefit for treated animals in the in vivo model.

Statistics:

  • 50% of patients with cholangiocarcinoma die within 6 months of diagnosis (see also Cholangio Cancer).
  • Sorafenib treatment resulted in Tyr(705) phospho-STAT3 dephosphorylation in three human CCA cell lines.
  • 70% of CCA cells treated with sorafenib showed reduced Mcl-1 expression (Blechacz et al., 2009).
  • The study found a significant survival benefit in rats treated with sorafenib in the in vivo model.

Sources:

  • Blechacz, B.R., et al. (2009). Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. Hepatology, 50(6), 1861-70.
  • (Source from NewsRx.com via Biotech Week).